Search Within

Jose T Baselga

  1. "Maura Dickler"
Formats
  1. Meeting Abstract (21)
  2. Journal Article (12)
Groups
  1. Breast Medicine Service (22)
  2. Department of Medicine (22)
  3. Solid Tumor Oncology Division (22)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (18)
  5. GSK Faculty (18)
  6. Epidemiology and Biostatistics (16)

More Groups

People
  1. Maura Dickler (33)
  2. Clifford Hudis (14)
  3. Sarat Chandarlapaty (13)
  4. Shanu Modi (13)
  5. Diana Lake (10)
  6. Gary Ulaner (10)

More People

Years
  1. 2020 (2)
  2. 2019 (1)
  3. 2018 (2)
  4. 2017 (11)
  5. 2016 (4)
  6. 2015 (9)

More Years

Publications
  1. Cancer Research (9)
  2. Journal of Clinical Oncology (8)
  3. Annals of Oncology (4)
  4. Clinical Cancer Research (3)
  5. Cancer Cell (2)
  6. Science (2)

More Publications

Publishers
  1. American Association for Cancer Research (13)
  2. American Society of Clinical Oncology (8)
  3. Oxford University Press (4)
  4. American Association for the Advancement of Science (3)
  5. Cell Press (2)
  6. American Medical Association (1)

More Publishers

Results (33)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Compound PIK3CA mutations support a mutational dose-response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer
    Meeting Abstract

    Vasan, N.; Johnson, J.; Shao, H.; Razavi, P.; Gorelick, A.; Ladewig, E.; Antoine, A.; Shah, H.; Toska, E.; Xu, G.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Ka inhibitors
    Journal Article

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Science (2019)

    Fulltext@MSK | Save
  • Phase II study of taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor-positive advanced breast cancer
    Journal Article

    Dickler, M. N.; Saura, C.; Richards, D. A.; Krop, I. E.; Cervantes, A.; Bedard, P. L.; Patel, M. R.; Pusztai, L.; Oliveira, M.; Cardenas, A. K.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • The genomic landscape of endocrine-resistant advanced breast cancers
    Journal Article

    Razavi, P.; Chang, M. T.; Xu, G.; Bandlamudi, C.; Ross, D. S.; Vasan, N.; Cai, Y.; Bielski, C. M.; Donoghue, M. T. A.; Jonsson, P.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease
    Meeting Abstract

    Cortés, J.; Rugo, H. S.; Tolaney, S. M.; Diéras, V.; Patt, D.; Wildiers, H.; Nanda, S.; Koustenis, A.; Dickler, M. N.; Baselga, J.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Oncologist use and perception of large panel next-generation tumor sequencing
    Journal Article

    Schram, A. M.; Reales, D.; Galle, J.; Cambria, R.; Durany, R.; Feldman, D.; Sherman, E.; Rosenberg, J.; D'Andrea, G.; Baxi, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing
    Journal Article

    Mandelker, D.; Zhang, L.; Kemel, Y.; Stadler, Z. K.; Joseph, V.; Zehir, A.; Pradhan, N.; Arnold, A.; Walsh, M. F.; Li, Y.; more...
    JAMA - Journal of the American Medical Association (2017)

    Fulltext@MSK | Save